Nurix Therapeutics Stock Forecast

Stock Price Forecast

According to 17 analysts polled by S&P Global, Nurix Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $30.47. The average 1-year stock price forecast is 94.70% higher than the current stock price, while the lowest is $23 (+46.96%) and the highest is $41 (+161.98%).

Price Target: $30.47 (+94.70%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$23	$30.47	$30	$41
Change	+46.96%	+94.70%	+91.69%	+161.98%

Analyst Ratings

The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	12	12	12	12	12	11
Buy	5	5	5	5	5	5
Hold	0	0	0	0	0	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	17	17	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Roger Song Jefferies	Jefferies	Buy Maintains $45	Buy	Maintains	$45	+187.54%	Jun 8, 2026
Gil Blum Needham	Needham	Buy Reiterates $26 → $34	Buy	Reiterates	$26 → $34	+117.25%	Jun 8, 2026
Derek Archila Wells Fargo	Wells Fargo	Hold Downgrades $28 → $25	Hold	Downgrades	$28 → $25	+59.74%	Jun 8, 2026
Gregory Renza Truist Financial	Truist Financial	Buy Reiterates $30 → $32	Buy	Reiterates	$30 → $32	+104.47%	Jun 8, 2026
Stephen Willey Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $34	Buy	Maintains	$34	+117.25%	May 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

53.19M

from 83.98M

-36.67%

from 83.98M

Revenue Next Year

74.16M

from 53.19M

39.43%

from 53.19M

EPS This Year

-2.95

from -3.05

EPS Next Year

-2.86

from -2.95

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Nov 30, 2021	Nov 30, 2022	Nov 30, 2023	Nov 30, 2024	Nov 30, 2025	Nov 30, 2026
Revenue	29.75M	38.63M	76.99M	54.55M	83.98M	53.19M
Revenue Growth	66.95%	29.84%	99.31%	-29.15%	53.95%	-36.67%
Gross Profit	-86.68M	-145.87M	-112.16M	-167.08M	-232.92M	53.19M
Gross Margin	-291.37%	-377.64%	-145.69%	-306.30%	-277.36%	100.00%
Operating Income	-117.89M	-183.87M	-155.06M	-213.03M	-285.67M	-352.90M
Net Income	-117.19M	-180.36M	-143.95M	-193.57M	-264.46M	-336.01M
EPS	-	-	-	-	-3.05	-2.95
Free Cash Flow	-37.70M	-79.42M	-41.93M	-85.90M	-143.99M	-284.50M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	121.3M
Avg	53.2M
Low	14.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	44.4%
Avg	-36.7%
Low	-82.7%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-2.95
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-